Daiichi Sankyo

Organon has partnered with Daiichi Sankyo Europe to distribute Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland, and Norway. This collaboration aims to increase patient access to Nilemdo®, a novel treatment for high cholesterol and cardiovascular disease risk, especially for those intolerant to statins. Organon will handle distribution and promotion, supporting its cardiovascular portfolio and addressing unmet patient needs, particularly for women who often experience statin intolerance.

AstraZeneca and Daiichi Sankyo’s DATROWAY met dual primary endpoints in the TROPION-Breast02 Phase III trial for locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) patients. DATROWAY demonstrated a statistically significant and clinically meaningful improvement in both overall survival (OS) and progression-free survival (PFS) versus chemotherapy. The trial showed a 43% reduction in disease progression or death risk and a 5-month improvement in median OS versus chemotherapy. Detailed results will be presented at the 2025 ESMO Congress.